WO2000052479A3 - Diagnostics and therapeutics for drusen associated ocular disorders - Google Patents

Diagnostics and therapeutics for drusen associated ocular disorders Download PDF

Info

Publication number
WO2000052479A3
WO2000052479A3 PCT/US2000/005858 US0005858W WO0052479A3 WO 2000052479 A3 WO2000052479 A3 WO 2000052479A3 US 0005858 W US0005858 W US 0005858W WO 0052479 A3 WO0052479 A3 WO 0052479A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutics
diagnostics
ocular disorders
associated ocular
drusen associated
Prior art date
Application number
PCT/US2000/005858
Other languages
French (fr)
Other versions
WO2000052479A2 (en
Inventor
Gregory S Hageman
Robert F Mullins
Original Assignee
Univ Iowa Res Found
Gregory S Hageman
Robert F Mullins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found, Gregory S Hageman, Robert F Mullins filed Critical Univ Iowa Res Found
Priority to AU33958/00A priority Critical patent/AU3395800A/en
Priority to EP00912189A priority patent/EP1161686A2/en
Priority to CA002363503A priority patent/CA2363503C/en
Publication of WO2000052479A2 publication Critical patent/WO2000052479A2/en
Publication of WO2000052479A3 publication Critical patent/WO2000052479A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Abstract

The invention relates to methods for treating, preventing and diagnosing drusen-associated disorders.
PCT/US2000/005858 1999-03-05 2000-03-06 Diagnostics and therapeutics for drusen associated ocular disorders WO2000052479A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU33958/00A AU3395800A (en) 1999-03-05 2000-03-06 Diagnostics and therapeutics for drusen associated ocular disorders
EP00912189A EP1161686A2 (en) 1999-03-05 2000-03-06 Diagnostics and therapeutics for drusen associated ocular disorders
CA002363503A CA2363503C (en) 1999-03-05 2000-03-06 Diagnostics and therapeutics for drusen associated ocular disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12305299P 1999-03-05 1999-03-05
US60/123,052 1999-03-05
US51023000A 2000-02-22 2000-02-22
US09/510,230 2000-02-22

Publications (2)

Publication Number Publication Date
WO2000052479A2 WO2000052479A2 (en) 2000-09-08
WO2000052479A3 true WO2000052479A3 (en) 2001-02-01

Family

ID=26821176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005858 WO2000052479A2 (en) 1999-03-05 2000-03-06 Diagnostics and therapeutics for drusen associated ocular disorders

Country Status (4)

Country Link
EP (1) EP1161686A2 (en)
AU (1) AU3395800A (en)
CA (1) CA2363503C (en)
WO (1) WO2000052479A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9279148B2 (en) 1999-04-20 2016-03-08 Illumina, Inc. Detection of nucleic acid reactions on bead arrays

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
CA2407715C (en) 2000-04-29 2009-03-24 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
CN103920142A (en) 2005-02-14 2014-07-16 爱荷华大学研究基金会 Methods And Reagents For Treatment Of Age-related Macular Degeneration
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
CA2621953A1 (en) * 2005-09-09 2007-03-22 University Of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof
AU2013274582A1 (en) 2012-06-11 2015-01-22 Macuclear, Inc. Therapeutic formulation and methods of treatment
GB201306627D0 (en) 2013-04-11 2013-05-29 Thompson Richard Marker
AU2014236782B2 (en) 2013-03-14 2019-01-03 Baxalta GmbH Factor H for treatment of rheumatoid arthritis
JP6373963B2 (en) 2013-03-14 2018-08-15 バクスアルタ インコーポレイテッド Factor H for transplantation
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
US9423394B2 (en) * 2013-12-13 2016-08-23 TheraOptix, Inc. Retinal pigment epithelial primary cell culture system producing subcellular deposits
WO2018039030A1 (en) 2016-08-23 2018-03-01 University Of Maryland, Baltimore Methods for detecting and/or predicting age-related macular degeneration and/or alzheimer's disease

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALLIKMETS R ET AL: "Mutation of the Stargardt Disease gene (ABCR) in Age-related Macular Degeneration", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 277, no. 277, 19 September 1997 (1997-09-19), pages 1805 - 1807, XP002099899, ISSN: 0036-8075 *
DETRICK B ET AL: "Class II antigen expression and gamma interferon modulation of monocytes and retinal pigment epithelial cells from patients with retinitis pigmentosa.", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, (1985 AUG) 36 (2) 201-11., XP000900830 *
ESSER P ET AL: "The significance of vitronectin in proliferative diabetic retinopathy.", GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, (1994 AUG) 232 (8) 477-81., XP000911976 *
GROSSNIKLAUS H E ET AL: "Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration.", AMERICAN JOURNAL OF OPHTHALMOLOGY, (1992 OCT 15) 114 (4) 464-72., XP000900850 *
HAGEMAN G S ET AL: "Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells.", FASEB JOURNAL, (1999 MAR) 13 (3) 477-84., XP002145241 *
HEIDENKUMMER H P ET AL: "[Surgical extraction of subretinal pseudotumors in age related macular degeneration. Clinical, morphologic and immunohistochemical results]. Chirurgische Extraktion subretinaler Pseudotumoren bei altersbezogener Makuladegeneration ( AMD ). Klinische, morphologische und immunohistochemische Ergebniss", OPHTHALMOLOGE, (1995 OCT) 92 (5) 631-9., XP000900831 *
KLAVER C C ET AL: "Genetic association of apolipoprotein E with age-related macular degeneration [published erratum appears in Am J Hum Genet 1998 Oct;63(4):1252].", AMERICAN JOURNAL OF HUMAN GENETICS, (1998 JUL) 63 (1) 200-6., XP000911959 *
MULLINS R F ET AL: "Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease.", FASEB JOURNAL, (2000 MAY) 14 (7) 835-46., XP002145240 *
SOUIED E H ET AL: "The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration.", AMERICAN JOURNAL OF OPHTHALMOLOGY, (1998 MAR) 125 (3) 353-9., XP000911975 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9279148B2 (en) 1999-04-20 2016-03-08 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US9441267B2 (en) 1999-04-20 2016-09-13 Illumina, Inc. Detection of nucleic acid reactions on bead arrays

Also Published As

Publication number Publication date
AU3395800A (en) 2000-09-21
WO2000052479A2 (en) 2000-09-08
CA2363503A1 (en) 2000-09-08
CA2363503C (en) 2009-03-10
EP1161686A2 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
CA2407715A1 (en) Diagnostics and therapeutics for macular degeneration-related disorders
WO2000052479A3 (en) Diagnostics and therapeutics for drusen associated ocular disorders
AU2002366641A1 (en) Methods for inhibiting ocular processes
HK1040266A1 (en) Titanium alloy and method for producing the same.
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
WO2003071927A3 (en) Diagnostics and therapeutics for macular degeneration-related disorders
AU2002325835A1 (en) Treatment method, which promotes the removal of dirt, for the surfaces of textiles and non-textiles
MXPA03007983A (en) Process for the preparation of middle distillates.
WO2001079461A3 (en) Polypeptides having haloperoxidase activity
ZA993364B (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
HK1049002A1 (en) Method for the preparation of citalopram.
ZA200006947B (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline.
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2000020470A3 (en) Aqueous dispersions
GC0000155A (en) 6-Hydroxy-indazole derivatives for treating glaucoma.
HK1052702A1 (en) Method for the preparation of 5-carboxyphthalide.
WO2001016377A3 (en) Diagnostics and therapeutics for osteoporosis
AU3824599A (en) Method for producing (s,s)-benzyl-2,8-diazabicyclo{4.3.0}nonane
MXPA03006607A (en) Combined method for treating hormono-dependent disorders.
ZA997027B (en) High-temperature, water-based lubricant and process for making the same.
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
ZA200002941B (en) Process for the preparation of butanediol, butyrolactone and tetrahydrofuran.
WO2002040480A3 (en) Crf receptor antagonists and methods relating thereto
CY2362B1 (en) Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis.
ZA994105B (en) Method for treating glaucoma.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2363503

Country of ref document: CA

Ref country code: CA

Ref document number: 2363503

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 33958/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000912189

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000912189

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)